Moleculin(MBRX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update - On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of R/R AML in Q1 2025 - Median durability of CRc in MB-106 Annamycin+ Cytarabine AML clinical trial continues to climb - now past 8 months - Recent virtual AML KOL event underscores how Annamycin could significantly ...